Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Neuen, Brendon L.; Heerspink, Hiddo J.L.; Vart, Priya; Claggett, Brian L.; Fletcher, Robert A.; Arnott, Clare; de Oliveira Costa, Julianna; Falster, Michael O.; Pearson, Sallie-Anne; Mahaffey, Kenneth W.; Neal, Bruce; Agarwal, Rajiv; Bakris, George; Perkovic, Vlado; Solomon, Scott D.; Vaduganathan, Muthiah

doi:10.1161/circulationaha.123.067584

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone all individually reduce cardiovascular, kidney, and mortality outcomes in patients with type 2 diabe…